Hematology

Glofitamab combined with GemOx shows promising survival benefits for patients with relapsed DLBCL, offering a new treatment option for those ineligible for transplants.

Ibrutinib offers comparable survival outcomes for high-risk chronic lymphocytic leukemia patients, challenging traditional prognostic markers in real-world settings.

The data are from the phase 2 iMMagine-1 study.

Patients with myelofibrosis who stopped ruxolitinib on the first day of conditioning did not show higher rates of acute graft-versus-host disease (GVHD).

There was no significant increase in severe adverse events associated with statin use.

The salvage therapy led to an 80% overall response rate in patients with relapsed/refractory multiple myeloma.

Liposomal annamycin demonstrates broad synergistic activity with multiple FDA-approved chemotherapies across hematologic and solid tumors in preclinical models, offering a promising and safer combination strategy for resistant and high-risk cancers.

Explore the latest advancements in treating transplant-ineligible multiple myeloma, highlighting new therapies and clinical trial outcomes for improved patient care.

Explore the role of JAK inhibitors in myelofibrosis treatment, focusing on optimizing dosages and managing adverse effects for better patient outcomes.

Explore the latest advancements in chronic lymphocytic leukemia treatment, focusing on BTK and BCL2 inhibitors, monoclonal antibodies, and patient management strategies.

Interim results from the phase 1 SENTI-202-101 trial show that SENTI-202, a logic-gated, off-the-shelf chimeric antigen receptor natural killer (CAR NK) cell therapy, achieved complete remission in 4 patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Obecabtagene autoleucel improves CAR T-cell therapy for B-cell ALL.

Clinicians should not just focus on one single nucleotide polymorphism (SNP), but rather consider all SNPs because each factor causes unique adverse effects

Thrombosis occurs in approximately 20% of myeloproliferative neoplasms.

Delayed pegaspargase reduces hepatotoxicity without affecting outcomes.

Real-world data support momelotinib as an effective and well-tolerated treatment for myelofibrosis-related anemia.

Undetectable minimal residual disease rates improved with ongoing therapy.

Current treatment strategies are aimed at reducing hematocrit and symptom burden through phlebotomy, aspirin, and cytoreductive agents, while emerging therapies offer promise for better disease control and quality of life.

Mark Zangardi, PharmD, MS, BCOP, and Amber Cipriani, PharmD, BCOP, discuss the growing role of circulating tumor DNA (ctDNA) testing in oncology, highlighting its applications in early cancer detection, molecular residual disease assessment, and treatment monitoring.

Matthew Lei, PharmD, BCOP, highlights the value of community, collaboration, and innovation at the HOPA Annual Conference.

The multiple myeloma landscape is evolving, with bispecific T-cell engagers offering hope.

The trial showed that adding pelabresib to ruxolitinib improved outcomes in myelofibrosis with manageable adverse effects.

CAV-1 is a key protein in lipid rafts that helps control cellular processes such as growth, survival, and migration.

Siremadlin is a novel, investigational, second-generation antagonist that binds to MDM2.

Real-time profiling of T-cell activation states in non-CAR T-cells may help guide treatment decisions.

Pharmacists performed weekly toxicity and tumor lysis syndrome monitoring.

Patients with chronic lymphocytic leukemia (CLL) show weakened T-cell memory responses to COVID-19 vaccination.

Using Janus kinase inhibitors, having experienced a previous thrombosis episode, and higher age were associated with a heightened risk of a new thromboembolic event.

Adding daratumumab improved minimal residual disease (MRD) negativity rates, leading to superior progression-free survival (PFS).